{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:06:36Z","timestamp":1788577596362,"version":"build-2803163510"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1681\/asn.2011030287","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T00:05:33Z","timestamp":1323389133000},"page":"334-342","source":"Crossref","is-referenced-by-count":54,"title":["Comparative Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin-Receptor Blockade on Inflammation during Hemodialysis"],"prefix":"10.1681","volume":"23","author":[{"given":"Jorge L.","family":"Gamboa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mias","family":"Pretorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna R.","family":"Todd-Tzanetos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Alp","family":"Ikizler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20230301","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease.","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R2-20-20230301","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1525-139X.1999.00006.x","article-title":"Epidemiology of cardiac disease in dialysis patients.","volume":"12","author":"Sarnak","year":"1999","journal-title":"Semin Dial"},{"key":"R3-20-20230301","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJM199809173391203","article-title":"Poor long-term survival after acute myocardial infarction among patients on long-term dialysis.","volume":"339","author":"Herzog","year":"1998","journal-title":"N Engl J Med"},{"key":"R4-20-20230301","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.semnephrol.2005.05.002","article-title":"Predictors of cardiovascular death in ESRD.","volume":"25","author":"Zoccali","year":"2005","journal-title":"Semin Nephrol"},{"key":"R5-20-20230301","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1525-139X.2009.00659.x","article-title":"Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy.","volume":"22","author":"Himmelfarb","year":"2009","journal-title":"Semin Dial"},{"key":"R6-20-20230301","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia.","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"},{"key":"R7-20-20230301","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5414\/CNP58190","article-title":"Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients.","volume":"58","author":"Ikizler","year":"2002","journal-title":"Clin Nephrol"},{"key":"R8-20-20230301","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1046\/j.1523-1755.2001.0590051960.x","article-title":"Elevated plasma F2-isoprostanes in patients on long-term hemodialysis.","volume":"59","author":"Handelman","year":"2001","journal-title":"Kidney Int"},{"key":"R9-20-20230301","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1523-1755.1998.00981.x","article-title":"Immunologic function and survival in hemodialysis patients.","volume":"54","author":"Kimmel","year":"1998","journal-title":"Kidney Int"},{"key":"R10-20-20230301","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00041552-200311000-00004","article-title":"Oxidative stress in uremia.","volume":"12","author":"Himmelfarb","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R11-20-20230301","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1492-7535.2005.01116.x","article-title":"Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysis-associated inflammation.","volume":"9","author":"Morena","year":"2005","journal-title":"Hemodial Int"},{"key":"R12-20-20230301","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1523-1755.2002.kid556.x","article-title":"Inflammatory signals associated with hemodialysis.","volume":"62","author":"Caglar","year":"2002","journal-title":"Kidney Int"},{"key":"R13-20-20230301","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/sj.ki.5001865","article-title":"Acute effects of hemodialysis on cytokine transcription profiles: Evidence for C-reactive protein-dependency of mediator induction.","volume":"70","author":"Friedrich","year":"2006","journal-title":"Kidney Int"},{"key":"R14-20-20230301","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1006\/jmcc.2002.2117","article-title":"Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1\u03b1, tumor necrosis factor-\u03b1, transforming growth factor-\u03b2 and oncostatin M in human cardiac myocytes.","volume":"34","author":"Macfelda","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"R15-20-20230301","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1681\/ASN.V1261255","article-title":"Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis.","volume":"12","author":"Segarra","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R16-20-20230301","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R17-20-20230301","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"R18-20-20230301","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies.","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"R19-20-20230301","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R21-20-20230301","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","article-title":"Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.","volume":"339","author":"Gainer","year":"1998","journal-title":"N Engl J Med"},{"key":"R22-20-20230301","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/jpet.106.104026","article-title":"Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans.","volume":"318","author":"Murphey","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R23-20-20230301","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.HYP.13.6.658","article-title":"Endothelium and control of vascular function. State of the art lecture.","volume":"13","author":"Vanhoutte","year":"1989","journal-title":"Hypertension"},{"key":"R24-20-20230301","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.regpep.2004.09.005","article-title":"Bradykinin upregulates IL-8 production in human gingival fibroblasts stimulated by interleukin-1\u03b2 and tumor necrosis factor \u03b1.","volume":"126","author":"Brunius","year":"2005","journal-title":"Regul Pept"},{"key":"R25-20-20230301","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bjp.0705236","article-title":"Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats.","volume":"139","author":"Santos","year":"2003","journal-title":"Br J Pharmacol"},{"key":"R26-20-20230301","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.freeradbiomed.2010.04.023","article-title":"Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism.","volume":"49","author":"Fong","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"R27-20-20230301","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/ATVBAHA.108.169367","article-title":"Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species.","volume":"29","author":"Larsen","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R28-20-20230301","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.1523-1755.1999.0550031097.x","article-title":"Activation of the kallikrein-kinin system in hemodialysis: Role of membrane electronegativity, blood dilution, and pH.","volume":"55","author":"Renaux","year":"1999","journal-title":"Kidney Int"},{"key":"R29-20-20230301","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1681\/ASN.2009050505","article-title":"Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.","volume":"20","author":"Marney","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R30-20-20230301","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2004.03.023","article-title":"Soluble CD40 ligand and platelets: Self-perpetuating pathogenic loop in thrombosis and inflammation?","volume":"43","author":"Aukrust","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R31-20-20230301","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000248135.97380.76","article-title":"Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.","volume":"48","author":"Luther","year":"2006","journal-title":"Hypertension"},{"key":"R32-20-20230301","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11906-001-0082-y","article-title":"Angiotensin, inflammation, hypertension, and cardiovascular disease.","volume":"3","author":"Luft","year":"2001","journal-title":"Curr Hypertens Rep"},{"key":"R33-20-20230301","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/01.ATV.19.7.1623","article-title":"Angiotensin induces inflammatory activation of human vascular smooth muscle cells.","volume":"19","author":"Kranzh\u00f6fer","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R34-20-20230301","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bjp.0705200","article-title":"Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury.","volume":"139","author":"Souza","year":"2003","journal-title":"Br J Pharmacol"},{"key":"R35-20-20230301","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-5793(89)81331-6","article-title":"Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages.","volume":"247","author":"Tiffany","year":"1989","journal-title":"FEBS Lett"},{"key":"R36-20-20230301","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.4049\/jimmunol.160.6.3038","article-title":"Role of the Rho GTPase in bradykinin-stimulated nuclear factor-kappaB activation and IL-1\u03b2 gene expression in cultured human epithelial cells.","volume":"160","author":"Pan","year":"1998","journal-title":"J Immunol"},{"key":"R37-20-20230301","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfg074","article-title":"Oxidative stress in end-stage renal disease: An emerging threat to patient outcome.","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R38-20-20230301","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/art.22445","article-title":"Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression.","volume":"56","author":"Brechter","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R39-20-20230301","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1165\/rcmb.2005-0369OC","article-title":"IL-1beta-induced transcriptional up-regulation of bradykinin B1 and B2 receptors in murine airways.","volume":"36","author":"Zhang","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R40-20-20230301","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/ndt\/17.9.1684","article-title":"Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment.","volume":"17","author":"Pecoits-Filho","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R41-20-20230301","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1046\/j.1523-1755.2002.00215.x","article-title":"Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients.","volume":"61","author":"Kato","year":"2002","journal-title":"Kidney Int"},{"key":"R42-20-20230301","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/00365590500386734","article-title":"Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients?","volume":"39","author":"Seyrek","year":"2005","journal-title":"Scand J Urol Nephrol"},{"key":"R43-20-20230301","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1523-1755.2002.00504.x","article-title":"Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events.","volume":"62","author":"Girndt","year":"2002","journal-title":"Kidney Int"},{"key":"R44-20-20230301","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/sj.ki.5001983","article-title":"Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.","volume":"70","author":"Aslam","year":"2006","journal-title":"Kidney Int"},{"key":"R45-20-20230301","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/ndt\/16.2.302","article-title":"Impaired endothelium-dependent vasodilatation in renal failure in humans.","volume":"16","author":"Annuk","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R46-20-20230301","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1681\/ASN.V12122747","article-title":"Oxidative stress and endothelial function in chronic renal failure.","volume":"12","author":"Annuk","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R47-20-20230301","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/hy0302.105767","article-title":"Smoking impairs bradykinin-stimulated t-PA release.","volume":"39","author":"Pretorius","year":"2002","journal-title":"Hypertension"},{"key":"R48-20-20230301","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/01.HYP.0000209952.30603.e9","article-title":"Blood pressure reduction and tissue-type plasminogen activator release.","volume":"47","author":"Brown","year":"2006","journal-title":"Hypertension"},{"key":"R49-20-20230301","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/ndt\/12.11.2355","article-title":"Plasma hypercoagulability in haemodialysis patients: Impact of dialysis and anticoagulation.","volume":"12","author":"Amb\u00fchl","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R50-20-20230301","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000046004","article-title":"D-dimers in hemodialysis patients.","volume":"88","author":"Miozzari","year":"2001","journal-title":"Nephron"},{"key":"R51-20-20230301","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/00365510310000989","article-title":"Haemostatic complications in haemodialysis patients: Effect of type of vascular access and dialysis filter.","volume":"63","author":"Yu","year":"2003","journal-title":"Scand J Clin Lab Invest"},{"key":"R52-20-20230301","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/01.ASN.0000081662.64171.9B","article-title":"Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis.","volume":"14","author":"Hocher","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R53-20-20230301","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2008.08.042","article-title":"ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study.","volume":"204","author":"Ceconi","year":"2009","journal-title":"Atherosclerosis"},{"key":"R54-20-20230301","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ahj.2008.10.026","article-title":"Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: Results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.","volume":"157","author":"Cesari","year":"2009","journal-title":"Am Heart J"},{"key":"R55-20-20230301","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","article-title":"ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.","volume":"73","author":"Ceconi","year":"2007","journal-title":"Cardiovasc Res"},{"key":"R56-20-20230301","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa022600","article-title":"Soluble CD40 ligand in acute coronary syndromes.","volume":"348","author":"Heeschen","year":"2003","journal-title":"N Engl J Med"},{"key":"R57-20-20230301","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1440-1797.2008.00999.x","article-title":"Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease.","volume":"13","author":"Lim","year":"2008","journal-title":"Nephrology (Carlton"},{"key":"R58-20-20230301","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2005.07.040","article-title":"Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.","volume":"108","author":"Koh","year":"2006","journal-title":"Int J Cardiol"},{"key":"R59-20-20230301","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/eurheartj\/ehi132","article-title":"Soluble CD40 ligand in acute and chronic heart failure.","volume":"26","author":"Ueland","year":"2005","journal-title":"Eur Heart J"},{"key":"R60-20-20230301","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.amjcard.2007.01.030","article-title":"Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.","volume":"99","author":"Tveit","year":"2007","journal-title":"Am J Cardiol"},{"key":"R62-20-20230301","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","article-title":"A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.","volume":"87","author":"Morrow","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R63-20-20230301","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/clinchem\/27.12.2048","article-title":"Optimized assay for serum angiotensin-converting enzyme activity.","volume":"27","author":"Hurst","year":"1981","journal-title":"Clin Chem"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201202000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:27:19Z","timestamp":1786130839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201202000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2011030287","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}